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Objective: To evaluate the effect of imatinib mesylate on cell viability, anti cancer effect
through modulation of KAI1/CD82 gene expression in breast cancer MCF-7 cell line.
Methods: The effects of imatinib mesylate on cell viability in MCF-7 cell line were
assessed using MTT assay and IC50 value was determined. GAPDH and KAI1/CD82 were
selected as reference and target genes, respectively. Quantitative real time PCR technique
was applied for investigation of KAI1/CD82 gene expression in human breast cancer
MCF-7 cells. Subsequently, the quantity of KAI1 compared to GAPDH gene expressions
were analyzed using the formula; 2−DDCt.
Results: Imatinib was showed to have a dose-dependent inhibitory effect on the viability
of MCF-7 cells. CD82/GAPDH gene expression ratios were 1.322 ± 0.030 (P > 0.05),
2.052 ± 0.200 (P < 0.05), 2.151 ± 0.270 (P < 0.05) for 10, 20 and 40 mmol/L of imatinib
concentrations.
Conclusions: Based on the present data, imatinib mesylate might modulate metastasis by
up-regulating KAI1/CD82 gene expression in human breast MCF-7 cancer cell line.1. Introduction
Breast cancer is the second leading cause of cancer related death
worldwide among women [1,2]. The high mortality and morbidity
associated with breast cancer derived from its metastasis to liver,
bone and lungs. The failure of conventional chemo- and radio-
therapy and increasing rate of death caused by invasive breast
cancer requires an urgent need to identify novel anti cancer drugand new targets for more proﬁtable treatments [3]. Currently,
different preclinical and clinical studies on molecular targeted
therapies agents have shown that it has great promise in the
treatment of different malignant tumors like breast cancer [4].
Imatinib mesylate (IM) (Gleevec; Novartis, Basel, Switzerland),
was ﬁrst used as a novel class of agents that suppress particular
tyrosine kinases. IM has been registered in adults for
monotherapy of chronic myeloid leukemia by inhibiting speciﬁcad University, Tehran, Iran.
ed by specially invited international editorial board
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induction of c-kit receptor kinases and platelet-derived growth
factor (ab) receptor which regulate majority of cellular events [5–7].
Moreover, IM is an important targeted therapy agent used widely
for inhibition of tumor growth in several malignancies including
ovarian, pancreatic, osteosarcoma, myeloid, thyroid and lung
cancer and is recently utilized in research and treatment of other
solid tumors [8,9]. Metastasis to bone is a common complication
of cancer patients, with up to 70% of patients due to malignant
cancer [10]. Understanding the gene expression during
progression of tumor has been the topic of intense method for
inhibition of tumor growth and targeting metastatic cascade.
Currently, metastasis suppressor genes are found to play an
important role in regulation of cell invasion and metastasis
signaling. KAI1 (CD82), a tumor metastasis suppressor gene, has
wide-spectrum roles in targeting tumor metastasis [11,12]. Many
studies have conﬁrmed that the KAI1/CD82 gene inhibits
metastasis in various types of cancers such as endometrial,
pancreatic, bladder, breast, ovarian, cervical, lung, hepatic,
colorectal and gastric cancer [13–15]. The main purpose of this
study is to determine the effect of various imatinib concentrations
on cell viability and metastasis through modulation of KAI1/
CD82 gene expression in breast cancer MCF-7 cell line.
2. Materials and methods
2.1. Cell culture
The human breast adenocarcinoma cell line (MCF-7) was
purchased from the National Cell Bank of Iran, Pasteur Institute,
Tehran, Iran. Cells were maintained in RPMI 1640 medium that
was supplemented with 10% fetal bovine serum, 1 mmol/L so-
dium pyruvate, 2 mmol/L glutamine, 1% penicillin/streptomycin
(all purchase from Gibco, Scotland) in an incubator environment
of 5% carbon dioxide (CO2) atmosphere at 37 C.
2.2. Cell viability assay
To determine cell viability, we used the MTT assay [12].
Different concentrations of imatinib ranging from 0, 1.5, 2.5,
5.0, 10.0, 20.0, and 40.0 mmol/L were treated into MCF-7
grown cells (1 × 104 cells/well) in 96-well microtiter plate and
incubated for 24 h at 37 C in order to further application. The
cells were treated with 10 mL of the MTT solution (5 mg/mL in
phosphate buffer) and incubated at 37 C for 4 h. Then, for
solubilization of the MTT formazan products, 100 mL of
dimethylsulfoxide (Merck, Germany) were added to the wells.
The optical density (OD) of each well was determined at a
wavelength of 570 nm with ELISA reader (Organon Teknika,
Netherlands). Finally, The OD value was determined as per-
centage of viability by the following formula:
Viability ð%Þ = OD value of samples
OD value of controls
× 100
The IC50 value of IM was calculated as the dose at with 50%
cell death occurred relative to the untreated cells.
2.3. RNA isolation and cDNA synthesis
MCF-7 cell line was seeded in 96 well plate with 5 × 104
cells per well and incubated for overnight, and then, the cellswere treated with IM. Total RNA was extracted using the RNA-
isolation kit (Qiagen, RNease Plus Mini Kit 50) according to the
manufacturer's instructions. The purity of the isolated RNA has
been performed by using a NanoDrop machine (IMPLEN,
Germany). RNA isolated with 260/280 nm absorption ratio >1.8
was subjected for cDNA synthesis. Complementary DNA syn-
thesis was ampliﬁed using Prime Script™ 1st strand cDNA
synthesis kit (Takara, Japan) in 20 mL reaction mixture con-
taining 4 mL Prime Script™ Buffer 5×, 3 mL of total RNA
(1 mg), 10 mmol/L dNTPs (1 mL), 50 mmol/L oligo dT primer
(1 mL), 50 mmol/L Random 6 mers (1 mL), 1 mL Prime Script™
RTase (200 units), 1 mL RNase inhibitor (40 units) and 8 mL
nuclease-free water. Relative quantitation of gene expression
was measured by ABI 2720 thermal cycler (Applied Biosystems,
USA) for 10 min at 30 C, 50 min at 42 C and 5 min at 95 C
followed by cooling on ice for 5 min.
2.4. Primer design
In the present investigation, the primers for real-time PCR of
GAPDH and KAI1 genes were designed using Primer Express
software v3.0.1. The forward and reverse primers used for KAI1/
CD82 gene were the (50 CTCAGCCTGTATCAAAGTCACCA
30) and (50 CCCACGCCGATGAAGACATA 30), respectively.
The sequence of the forward primer for reference gene GAPDH
was 50 CGTCTGCCCTATCAACTTTCG 30 and that of reverse
primer was 50 CGTTTCTCAGGCTCCCTCT 30. The speciﬁcity
of the selected primers was tested using BLAST tool (www.
ncbi.nlm.nih.gov/blast).
2.5. Quantitative data analysis of real-time PCR
A SYBR Green real-time PCR was performed on cDNA iso-
lated fromMCF-7 cells after treatment with IM. The expression of
target gene was quantiﬁed by using an ABI 7300 real-time PCR
system, according to the following conditions: 95 C for 10min, 40
cycles were followed at 95 C for 15 s and 60 C for 1 min.
Ampliﬁcation stage was followed by a melting stage at 95 C for
20 s, 60 C for 1 min and 95 C for 20 s. The ampliﬁcation reaction
was carried out at total volume of 20 mL, including 2 mL cDNA
sample (100 ng), 1mLof primers (0.4mmol/L), 10mLSYBRGreen
PCR master mix (2×) and 6 mL double-distilled water. The gene
expression was measured by comparative threshold cycle (Ct)
values throughout the exponential phase of ampliﬁcation. During
each assay, mCt values were the mean of threshold cycle of Ct
values. Relative quantity of target genes (KAI1/CD82) was eval-
uated using comparative Ct method andDCt value was determined
as the difference between the Ct of target and the Ct of reference
gene. The relative quantity of KAI1/CD82 gene expression
compared to GAPDH gene was calculated applying the gene
dosage ratio formula (Gene dosage ratio = 2−DDCt). Where
DDCt = (mCt CD82 − mCt GAPDH)normal sample − (mCt
CD82 − mCt GAPDH)test sample. Gel electrophoresis was used to
approve the ampliﬁcation of PCR products and primer speciﬁcity.
The fragments of PCR products were separated by electrophoresis
in 1.5% agarose gels in 0.5× tetrabromoethane buffer.
2.6. Statistical analysis
The experimental data were performed at least in triplicate
and results were expressed as mean ± SEM. P-values <0.05
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using student's t-test between sample and control.
3. Results
3.1. MTT assay results
Different concentrations of IM have cytotoxicity effect on
MCF-7 cancer cells at 24 h. At concentrations of 1.5, 2.5, 5.0,
10.0, 20.0 and 40.0 mmol/L of IM the viability of MCF-7 was
declined to (70.080 ± 0.030)% (P > 0.05), (60.480 ± 0.003)%
(P < 0.05), (34.500 ± 0.008)%, (29.110 ± 0.005)% (P < 0.01),Figure 1. Viability percentage measured by MTT assay on MCF-7 cells
exposed to 0, 1.5, 2.5, 5.0, 10.0, 20.0 and 40.0 mmol/L of imatinib mesylate
after 24 h.
Data are reported as mean ± SEM from 3 independent experiments. Results
were statistically analyzed with a student's t-test. *: P < 0.05; **: P < 0.01;
***: P < 0.001.(17.520 ± 0.002)% and (9.160 ± 0.007)% (P < 0.001), respec-
tively (Figure 1). The IC50 of IM on breast cancer MCF-7 cell
line was calculated to be 8.96 mmol/L.Figure 2. The melting curve of GAPDH gene and CD82 gene and gel
electrophoresis analysis of the PCR products.
A: The melting curve at 82.4 C for GAPDH gene and 81.1 C for CD82
gene indicated the speciﬁc products that melt at the different temperatures.
Flat peak demonstrates non template control (NTC); B: Gel electrophoresis
analysis of the PCR products. Lane 1: 102 bp PCR product of GAPDH gene.
Lane 2: NTC for GAPDH gene. Lane 3: 183 bp PCR product of CD82 gene.
Lane 4: NTC for CD82 gene; M: Molecular Size marker-100 bp ladder.3.2. Melting curve analysis and gel electrophoresis
The melting curve analysis was evaluated based on DRn
derivation (derivative of ﬂuorescence over temperature) (y axis)
and the temperature at x axis. It was created to document single
reaction formation without non-speciﬁc products and screen for
primer dimmers of desired genes. The melting peaks have been
drawn at 81.1 C for KAI1/CD82 gene and 82.4 C GAPDH
gene as shown in Figure 2A. Moreover, gel electrophoresis
analysis of PCR product revealed speciﬁc ampliﬁcation of genes
with the expected size (Figure 2B).
3.3. Relative quantiﬁcation analysis using ampliﬁcation
plots
Evaluation of relative gene expression between treated and
untreated samples can be measured by the difference in their Ct
values during exponential phase of ampliﬁcation. The value of
mCt for GAPDH gene was 17.45 at various concentrations of
IM. The mCts values for KAI1/CD82 gene were 26.96, 26.08,
25.49, and 35.68 at different concentrations of IM ranging from
0, 10.0, 20.0, and 40.0 mmol/L, respectively. The mCt value for
untreated samples was scaled as 17.49. The mCt values were
scaled as 8.63, 7.99 and 7.92 for 10.0, 20.0, 40.0 mmol/L of IM
concentrations. The DDCt values for treated samples at 10.0,Figure 3. Up regulation of KAI1/CD82 gene expression in human breast
adenocarcinoma (MCF-7) cell line treated with various concentrations of IM.20.0, 40.0 mmol/L IM concentrations were scaled
as −0.402, −01.037, and −1.105, respectively. Finally, the gene
dosage ratios (2−DDCt) were calculated as 1.322 ± 0.030
(P > 0.05), 2.052 ± 0.200 (P < 0.05) and 2.151 ± 0.270
(P < 0.05) at 10.0, 20.0 and 40.0 mmol/L of drug concentrations
(Figure 3).
4. Discussion
Over a million women throughout the world each year are
diagnosed with breast cancer which accounts for 25% of all
female cancers. The most frequent localization of tumor cells in
metastasis such as liver, bone and lungs are dangerous during
malignancy of breast cancer. Metastases to bone from breast
cancer affect 65–80 percent of patients with progressive malig-
nancy [16].
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inhibitors for the treatment of certain cancers that often induce
apoptosis and slow progression growth of bone metastases in
neoplastic cells which has been recently under examination in
clinical trials for malignant gliomas, carcinoid tumor, prostate
and ovarian cancer [17]. IM interferes with a speciﬁc molecular
target included in progression and tumor growth. These targets
such as cell-cycle proteins, growth factor receptors, signaling
molecules, modulators of apoptosis, and molecules involved in
invasion and angiogenesis, which are necessary for development
in normal tissues. Nowadays, many researchers showed the in-
vitro cytotoxicity effects of imatinib on various cancer cell lines
[18]. In the present study, we demonstrated that IM exerted a
dose-dependent inhibitory effect on the viability of highly
metastatic breast adenocarcinoma (MCF-7) cells. Treatment of
MCF-7 cells with IM induced the morphological changes which
revealed the increase in apoptotic cell population. Tumor
metastasis is the most lethal characteristic of a cancer, and it is
considered as the most signiﬁcant contributor to cancer related
mortality and morbidity [19]. Tumor metastasis is a very complex
process, which involves various stages and several cytophysio
logical changes including invasion into the extracellular
matrix, migration into bloodstream followed by the extravasate
from the circulatory system and initiate colonize distant sites
in secondary organ tissues.
Recently, identiﬁcation of the gene expression during tu-
mor progression has been the great signiﬁcant of intense
method for prognosis and therapy. At the ﬁrst time, KAI1/
CD82 was discovered as a tumor metastasis suppressor in
metastatic prostate cancer cells. KAI1 was later identiﬁed to be
metastasis suppressor gene during tumor growth in several
solid tumors. It has been shown that KAI1/CD82 suppresses
metastasis by various mechanisms involving inhibition of in-
vasion and motility, induction of apoptosis and senescence in
response to extracellular stimuli [20]. Several studies revealed
that there are an association between reduced expression of
KAI1/CD82 and increasing metastatic ability in human
malignant tumors such as bladder, cervical, ovarian, breast,
prostate and hepatocellular carcinoma [21,22]. The interactions
of KAI1/CD82 with several molecules such as epidermal
growth factor receptors, chemokines and integrins are likely
to play a signiﬁcant role in cell–cell interaction, signaling
and motility of cells, which infer an important role of this
gene [23,24]. Other studies showed that Bax, Bad, Bcl2,
PDGF, c-kit genes were differently regulated by imatinib
mesylate [18,24,25]. In 2009, Weigel M. et al. found that
combination of imatinib and vinorelbine induced apoptotic
cell death in ﬁve human breast adenocarcinoma cells [26].
Fernandes B. et al. reported that treating of an animal model
with imatinib resulted in 10-fold up regulation of KiSS-1
metastasis suppressor gene, which was then identiﬁed as a
human metastatic suppressor gene [27]. The consequential
ﬁnding in our study indicated that imatinib can up-regulate
KAI1/CD82 gene expression in human breast cancer cell line
which has not yet been reported. This is the ﬁrst report
depicting signiﬁcant inhibition of proliferation and increased
expression of KAI1/CD82 gene in breast cancer MCF-7 cells
line. Therefore, imatinib remains a promising candidate for the
treatment of breast cancer in the future.
In this study we demonstrated that treatment with imatinib for
24 h induces a dose-dependent inhibitory manner on the MCF-7
cells. Also, IM can induce up-regulation of KAI1/CD82 mRNAlevels in MCF-7 in a dose-dependent manner. Based on these re-
sults, imatinib probably increases expression of KAI1/CD82 gene
in breast cancer MCF-7 cells. Future subsequent clinical studies on
animal tumor models are required to conﬁrm our ﬁnding.
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